BR112022004630A2 - Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) - Google Patents

Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)

Info

Publication number
BR112022004630A2
BR112022004630A2 BR112022004630A BR112022004630A BR112022004630A2 BR 112022004630 A2 BR112022004630 A2 BR 112022004630A2 BR 112022004630 A BR112022004630 A BR 112022004630A BR 112022004630 A BR112022004630 A BR 112022004630A BR 112022004630 A2 BR112022004630 A2 BR 112022004630A2
Authority
BR
Brazil
Prior art keywords
prmt5
inhibitors
protein arginine
arginine methyltransferase
selective protein
Prior art date
Application number
BR112022004630A
Other languages
English (en)
Inventor
Ganfeng Cao
Hongwu Yu
Huaping Zhang
Qun Li
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of BR112022004630A2 publication Critical patent/BR112022004630A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

inibidores seletivos da proteína arginina metiltransferase 5 (prmt5). a revelação é direcionada a sais farmaceuticamente aceitáveis do composto de fórmula i (i). também são descritas composições farmacêuticas que compreendem sais farmaceuticamente aceitáveis do composto de fórmula i, bem como a métodos de seu uso e preparação.
BR112022004630A 2019-09-18 2020-09-18 Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) BR112022004630A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
BR112022004630A2 true BR112022004630A2 (pt) 2022-05-31

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004630A BR112022004630A2 (pt) 2019-09-18 2020-09-18 Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)

Country Status (11)

Country Link
US (1) US20230029094A1 (pt)
EP (1) EP4031555A1 (pt)
JP (1) JP2022548689A (pt)
KR (1) KR20220065811A (pt)
CN (1) CN114829370A (pt)
AU (1) AU2020349553A1 (pt)
BR (1) BR112022004630A2 (pt)
CA (1) CA3154566A1 (pt)
IL (1) IL291417A (pt)
MX (1) MX2022003340A (pt)
WO (1) WO2021055797A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
EP3665179B1 (en) * 2017-08-09 2021-06-09 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112020018636A2 (pt) * 2018-03-14 2020-12-29 Prelude Therapeutics, Incorporated Inibidores seletivos de proteína arginina metiltransferase 5 (prmt5)

Also Published As

Publication number Publication date
EP4031555A1 (en) 2022-07-27
KR20220065811A (ko) 2022-05-20
MX2022003340A (es) 2022-06-14
AU2020349553A1 (en) 2022-04-07
CA3154566A1 (en) 2021-03-25
CN114829370A (zh) 2022-07-29
JP2022548689A (ja) 2022-11-21
WO2021055797A9 (en) 2021-04-22
IL291417A (en) 2022-05-01
US20230029094A1 (en) 2023-01-26
WO2021055797A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
BR112017017135A2 (pt) inibidores de tgf-beta
PH12019502052A1 (en) Hepatitis b virus surface antigen inhibitor
BR112014033080A2 (pt) inibidores do vírus da hepatite c
BR112012024199A2 (pt) derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
MX2021005463A (es) Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1).
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
NI200900134A (es) Derivados de imidazol como inhibidores de proteína de huso de cinesina (eg-5).
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112022004327A2 (pt) Inibidores de cdk e seu uso como fármacos
MX2021009796A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
MX2020003993A (es) Derivados de bencimidazol y sus usos.
BR112021018950A2 (pt) Compostos de imidazolonilquinolina e seus usos terapêuticos
BR112015021768A2 (pt) inibidores do vírus da hepatite c
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
EA202192845A1 (ru) Новые композиции, содержащие мелфлуфен
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
BR112021011325A2 (pt) Derivados de rapamicina
MX2020009555A (es) Inhibidores selectivos de proteina arginina-metiltransferasa 5 (prmt5).
BR112022004630A2 (pt) Inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones